These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
98 related articles for article (PubMed ID: 330064)
41. Inhibition of thrombin by antithrombin III and heparin cofactor II in vivo. Liu L; Dewar L; Song Y; Kulczycky M; Blajchman MA; Fenton JW; Andrew M; Delorme M; Ginsberg J; Preissner KT Thromb Haemost; 1995 Mar; 73(3):405-12. PubMed ID: 7545318 [TBL] [Abstract][Full Text] [Related]
42. [Role of newly developed technology in blood coagulation disorders]. Matsuo T Rinsho Byori; 2002 May; 50(5):506-12. PubMed ID: 12078050 [TBL] [Abstract][Full Text] [Related]
43. Dermatan sulfate is a more potent inhibitor of clot-bound thrombin than unfractionated and low molecular weight heparins. Bendayan P; Boccalon H; Dupouy D; Boneu B Thromb Haemost; 1994 May; 71(5):576-80. PubMed ID: 8091383 [TBL] [Abstract][Full Text] [Related]
44. Regulation of Primary Polymerization of Fibrin by Blood Anticoagulant System Components. Lyapina LA; Maistrenko ES Bull Exp Biol Med; 2017 May; 163(1):46-48. PubMed ID: 28580517 [TBL] [Abstract][Full Text] [Related]
45. An antithrombin-heparin complex increases the anticoagulant activity of fibrin clots. Smith LJ; Mewhort-Buist TA; Berry LR; Chan AK Res Lett Biochem; 2008; 2008():639829. PubMed ID: 22820671 [TBL] [Abstract][Full Text] [Related]
46. A new non-thrombogenic surface prepared by selective covalent binding of heparin via a modified reducing terminal residue. Larm O; Larsson R; Olsson P Biomater Med Devices Artif Organs; 1983; 11(2-3):161-73. PubMed ID: 6667322 [TBL] [Abstract][Full Text] [Related]
47. Proceedings: The heparin-thrombin clotting time in clinical medicine. O'Brien JR; Etherington M; Lawford P J Clin Pathol; 1974 Nov; 27(11):928. PubMed ID: 4475050 [No Abstract] [Full Text] [Related]
48. The enzymatic action of thrombin and the physical phase of fibrin clotting. KOWARZYK H; GLOGOWSKA I; SZYMIK S Arch Immunol Ther Exp (Warsz); 1961; 9():341-55. PubMed ID: 14459049 [No Abstract] [Full Text] [Related]
49. Fundamental interactions and effect of storage, ether, adsorbants and blood clotting on plasma antithrombin activity. SEEGERS WH; MILLER KD; ANDREWS EB; MURPHY RC Am J Physiol; 1952 Jun; 169(3):700-11. PubMed ID: 14943864 [No Abstract] [Full Text] [Related]
50. Inactivation of alpha- and beta-thrombin by heat defibrinated human plasma. Effect of heparin. Orakzai SA; Machovich R Thromb Res; 1977 Jun; 10(6):813-22. PubMed ID: 882966 [No Abstract] [Full Text] [Related]
51. Rapid recovery of non-hemolyzed serum and untraumatized cells by using a new method of blood defibrination in vitro. Kay HD; Petrie HT; Burge JJ; Klassen LW J Immunol Methods; 1986 Sep; 92(2):251-60. PubMed ID: 3760585 [TBL] [Abstract][Full Text] [Related]
52. Detection of small amounts of heparin by the thrombin clotting-time. Eika C; Godal HC; Kierulf P Lancet; 1972 Aug; 2(7773):376. PubMed ID: 4114736 [No Abstract] [Full Text] [Related]
53. The relationship between the peptidase, esterase and clotting activity of thrombin. RONWIN E Acta Haematol; 1960 Mar; 23():129-39. PubMed ID: 14438697 [No Abstract] [Full Text] [Related]
54. Similarity to Heparin of the Clotting Inhibitor in Acute Leucemia and the Significance of Hyperheparinemia in Estrapenic Cholinergic States. Barnard RD Science; 1948 May; 107(2787):571-2. PubMed ID: 17779205 [No Abstract] [Full Text] [Related]
55. A heparin-retarded plasma clotting test. POLLER L Angiology; 1954 Feb; 5(1):21-6. PubMed ID: 13124814 [No Abstract] [Full Text] [Related]